Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

IBI Blog On Amarin And Clovis: Are You Profiting Big?

|About: Amarin Corporation plc (AMRN), CLVS
Summary

During the initial 5-rallying days, IBI members banked 68.9% gain. Following more recommendations, they boosted their net profit to 186.1% in the last 23-days.

Members who played the Amarin ADCOM catalyst also enjoyed 39.7% profit. As I forecasted, Amarin shares traded trade sideways for the past 3-days.

I don't want you to miss out again because I updated IBI members every morning about "high probability events."

If you haven't made a dime, you need to learn about "probability event forecasting" that IBI members use to catch rallies and avoid drops.

As part of my higher-level market intelligence, probability events analysis allows you to unlock the power of fundamental research. That is to say, it tells you when stocks rally and tumble.

That way, you don't have to wait years for the fundamentals for a stock to move. You can focus on stocks having high probability events for trading.

Sounds too good to be true right?

Well, IBI members continued to gain 186.1% profits on  Clovis Oncology (NASDAQ:CLVS). They also captured a 39.7% profit on the Amarin (AMRN)'s ADCOM play.

Last night, a member asked me this million dollars question.

To get him an answer, I analyzed all data points of Clovis by leveraging my fundamental research. Now after my data analysis, I let it sink in for my instinct to forecast the next high probability event for this stock.

As it turned out, today Clovis continued to hit another high probability event with 18.59% rally. That being said, if you're into Clovis, you should check out my latest high-level research.

Now keep in mind, the market is in constant flux.

That's why you don't see the share price of Amarin or Clovis staying the same. With new developments and news releases, you need to figure out how they act together. That way, you'll know where your stock is heading.

But that's not all!

You must gauge how investor sentiment will change and thereby position your trades to capture profits.

I have good news for you. I did all the hard work to give you an edge!

Members already accessed my market intelligence this morning which gave them a head start.

To know where Amarin and Clovis stocks will trade this week, you need market intelligence beforehand. Without a roadmap, you can have the best ship in the world but you won't reach your destination!

When it comes to profitability, market intelligence and timing are everything. You don't have to believe me but if you don't focus on those factors, you're not banking as much profits as you could.

Better yet, I want to help you hone your skills instead of giving you the fish alone. That way, you can become an expert yourself. If you're into Amarin, be sure to use my exclusive research to give you an advantage over the market.

Thanks for reading! Please hit the orange “Follow” button on top for more. And don’t miss out on the most profitable content (i.e. higher-level intelligence) inside IBI.

Here are what members said:

Dr. Tran's analyses are the best in the biotech sphere, well worth the price of subscription.

Very professional, extremely knowledgeable and very honest … I would highly recommend this service and his stock picks have been very profitable.

Simply put, this is worth every penny. Just earlier today, one of the companies recommended by Dr. Tran got acquired for a nice 50% premium.

Still not satisfied? Check out some more testimonies below. There are also countless reviews from physicians, market leaders, and financial experts.

I'm so confident in the value of my service that I'm giving you a 2-week FREE trial, money-back guarantee.

GET YOUR FREE GIFT TO PROFITABILITY NOW!

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Additional disclosure: As a medical doctor/market expert, I’m not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates at any time pertaining to any security without notification except where it is required by law. I am also NOT responsible for the actions of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investment in stocks and options can result in a loss of capital. The information presented should NOT be construed as a recommendation to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your actions. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized.